LinkedIn Profile

Access Karyopharm Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:kpti 2132519 Mar 23rd, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 407.00 Open Mar 22nd, 2024 11:49PM Mar 23rd, 2024 06:59PM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As leaders in XPO1 inhibition whose mission is to improve lives and defeat cancer, Karyopharm has created a focused pipeline targeting multiple high, unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 22nd, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 407.00 Open Mar 21st, 2024 11:40PM Mar 22nd, 2024 06:47PM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As leaders in XPO1 inhibition whose mission is to improve lives and defeat cancer, Karyopharm has created a focused pipeline targeting multiple high, unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 21st, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 407.00 Open Mar 20th, 2024 11:52PM Mar 21st, 2024 05:31PM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As leaders in XPO1 inhibition whose mission is to improve lives and defeat cancer, Karyopharm has created a focused pipeline targeting multiple high, unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 20th, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 407.00 Open Mar 20th, 2024 12:28AM Mar 20th, 2024 07:31PM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 19th, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 407.00 Open Mar 18th, 2024 11:28PM Mar 19th, 2024 06:04PM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 18th, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 407.00 Open Mar 17th, 2024 11:49PM Mar 18th, 2024 07:16PM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 17th, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 407.00 Open Mar 17th, 2024 01:25AM Mar 17th, 2024 01:25AM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 16th, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 407.00 Open Mar 15th, 2024 11:19PM Mar 16th, 2024 07:03PM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 15th, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 409.00 Open Mar 15th, 2024 12:44AM Mar 15th, 2024 08:53AM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:kpti 2132519 Mar 14th, 2024 12:00AM Karyopharm Therapeutics Inc. 30K 409.00 Open Mar 13th, 2024 11:17PM Mar 14th, 2024 12:14PM Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. Open oncology, pharmaceutical, biotech, multiplemyeloma, lymphoma, solidtumors, glioblastoma, clinicalresearch, clinicaltrials, research, drugdiscovery, medical, and healthcare Open 85 Wells Avenue Newton MA US 02459 Karyopharm Therapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.